PRIMARY PERITONEAL CARCINOMA

This early-phase trial tested a new treatment called Radspherin for women with ovarian cancer that has returned and spread in the abdomen. Radspherin consists of tiny radioactive particles injected directly into the belly after surgery to remove visible tumors. The study involved…

This study tested a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to prior treatments. STRO-002 is an antibody-drug conjugate, meaning it combines a targeted antibody with a chemotherapy drug to deli…

This study tests a new drug called ZN-c3 (azenosertib), either alone or combined with niraparib, in 117 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find safe doses and see if the drugs can shrink tumors. It is an early-stage trial, s…

This early-phase study tested whether adding a new drug called LDE225 to standard chemotherapy (paclitaxel) is safe for women with ovarian cancer that no longer responds to platinum-based treatments. Fifteen participants were monitored for side effects and to find the best dose. …

This trial studied 211 women with advanced ovarian cancer who were not candidates for upfront surgery. Researchers compared having surgery after 3 rounds of chemotherapy versus after 6 rounds. The goal was to see which timing leads to longer disease-free survival. All patients re…

This study tested a new drug called RP-6306 in 28 people with advanced cancer that could not be cured. The goal was to see if adding RP-6306 to standard treatment helps shrink tumors and is safe. Researchers also looked for specific biomarkers to see if some patients respond bett…

This early-phase study tested a new drug called SL-172154 combined with either of two standard chemotherapies in 86 people with ovarian cancer that had stopped responding to platinum-based treatment. The main goals were to check safety and find the best dose. Researchers also loo…

This Phase 2 trial tested whether adding afuresertib (an AKT inhibitor) to standard paclitaxel chemotherapy helps control platinum-resistant ovarian cancer better than paclitaxel alone. 150 women with this difficult-to-treat cancer participated. The study measured how long the ca…

This phase II trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before surgery helps women with stage IV ovarian cancer. 91 participants received either chemo alone or chemo plus pembrolizumab, followed by surgery. The goal was t…

This study tested a drug called M701, given directly into the belly, combined with standard cancer therapy, for people with malignant ascites (fluid buildup) from stomach, colon, or ovarian cancer. The goal was to see if M701 could delay the need for fluid drainage and improve su…

This study looked at 1,500 women with advanced ovarian, peritoneal, or fallopian tube cancer to see how genetic changes in their tumors relate to how the disease progresses. Researchers collected tumor samples and medical data to find links between DNA abnormalities and outcomes …

This study tested whether it is practical to routinely check ovarian cancer tumors for BRCA gene mutations in the clinic. Researchers enrolled 200 patients with high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. They used blood and tumor samp…

This study looked at how behavioral factors, hormones, and natural body chemicals might influence tumor growth in ovarian cancer. Researchers studied 613 women with ovarian cancer to understand these connections. The goal was to gather knowledge, not to test a treatment.

This study tested whether saliva samples can be used to remotely monitor cytomegalovirus (CMV) infection in people receiving treatment for ovarian cancer. Researchers compared saliva and blood samples from 49 participants, collected either at the clinic or at home. The goal was t…